Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology

02 May 2018

• By Joseph Haas, Ian Haydock, and Lucie Ellis-Taitt

Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.

Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology

More from Deals

More from Business